Myriad myRisk™ Hereditary Cancer is a 25-gene panel that helps to determine a patient’s risk by evaluating a number of hereditary cancer syndromes, with focus on eight primary cancer sites.
COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.
COLARIS AP ® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.
MELARIS® testing assesses a person’s risk of developing hereditary melanoma by detecting inherited mutations in the p16 gene (also called CDKN2A or INK4A ).
PANEXIA® testing assesses a person’s risk of developing hereditary pancreatic cancer by analyzing the PALB2 and BRCA2 genes, which are most commonly mutated in families with hereditary pancreatic cancer.
Myriad myPlan™ Lung Cancer is a molecular diagnostic test that measures the expression levels of cell cycle progression genes to provide an accurate assessment of cancer aggressiveness in early-stage non-small cell lung cancer.
Myriad myPath™ Melanoma is a unique molecular diagnostic test that analyzes 23 genes to assist in the timely and accurate diagnosis of melanoma.
Prolaris® is a molecular diagnostic test that measures the expression level of genes involved with tumor proliferation to predict disease outcome. Prolaris® can be used in conjunction with other clinical parameters to determine prostate cancer aggressiveness.
Vectra® DA is a multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and reproducible measure of rheumatoid arthritis (RA) disease activity.
PREZEON® testing assesses loss of PTEN function in cancer patients, which is associated with more aggressive disease progression and poorer survival rates.